You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
NEW YORK (GenomeWeb News) – The Massachusetts Life Sciences Center announced on Wednesday it has awarded Firefly BioWorks a $500,000 matching grant.
NEW YORK (GenomeWeb News) – Isogen Life Science will distribute Axela's multiplex biomarker platforms in Benelux and Spain under an agreement announced by the firms today.
NEW YORK (GenomeWeb News) – The US Food and Drug Administration has given 510(k) clearance for five additional pathogens for Idaho Technology's FilmArray Respiratory Panel, the company said today.
NEW YORK (GenomeWeb News) – San Diego-based Ridge Diagnostics today said that it has licensed exclusive rights to Ameritox to its MDDScore, a multiplex biomarker test for major depressive disorder.
NEW YORK (GenomeWeb News) – Genalyte today announced the completion of a Series B financing that raised $11.8 million.
NEW YORK (GenomeWeb News) – Bristol-Myers Squibb and Meso Scale Discovery today announced a deal to develop assays for use in Alzheimer's disease research.
NEW YORK (GenomeWeb News) – Privately held Quantiscientifics today said that BioDot will co-market and sell its A2 MicroArray System.
NEW YORK (GenomeWeb News) – Genetic Technologies today said that it has received a CLIA Certificate of Compliance for its Australian lab from the US centers for Medicare and Medicaid Services.
The purchase would provide Luminex access to a "highly complementary" portfolio of molecular diagnostic assays.
The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.
The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.
Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.
In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.